These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 16843100)

  • 1. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis.
    Athanasiadou A; Stamatopoulos K; Tsompanakou A; Gaitatzi M; Kalogiannidis P; Anagnostopoulos A; Fassas A; Tsezou A
    Cancer Genet Cytogenet; 2006 Jul; 168(2):109-19. PubMed ID: 16843100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
    Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
    Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
    Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS
    Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
    Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
    Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic aberrations and survival in chronic lymphocytic leukemia.
    Döhner H; Stilgenbauer S; Benner A; Leupolt E; Kröber A; Bullinger L; Döhner K; Bentz M; Lichter P
    N Engl J Med; 2000 Dec; 343(26):1910-6. PubMed ID: 11136261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
    Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
    Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.
    Kienle DL; Korz C; Hosch B; Benner A; Mertens D; Habermann A; Kröber A; Jäger U; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2005 Jun; 23(16):3780-92. PubMed ID: 15867199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of different chromosomal aberrations on molecular cytogenetic parameters in chronic lymphocytic leukemia.
    Amiel A; Leopold L; Gronich N; Yukla M; Fejgin MD; Lishner M
    Cancer Genet Cytogenet; 2006 Jun; 167(2):145-9. PubMed ID: 16737914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
    J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression.
    Molica S; Vitelli G; Levato D; Giannarelli D; Vacca A; Cuneo A; Ribatti D; Digiesi G
    Eur J Haematol; 2004 Jul; 73(1):36-42. PubMed ID: 15182336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia.
    Zenz T; Döhner H; Stilgenbauer S
    Best Pract Res Clin Haematol; 2007 Sep; 20(3):439-53. PubMed ID: 17707832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
    Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
    Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chromosome study on chronic lymphocytic leukemia using CpG-oligodeoxynucleotide as immunostimulant agent].
    Wu Y; Xue Y; Chen S; Yao L; Jiang H; Zhang J; Shen J; Pan J; Wang Y; Bai S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):86-91. PubMed ID: 20140876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect.
    Dickinson JD; Joshi A; Iqbal J; Sanger W; Bierman PJ; Joshi SS
    Int J Mol Med; 2006 May; 17(5):769-78. PubMed ID: 16596259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice.
    Doubek M; Mayer J; Obrtlíková P; Smolej L; Cmunt E; Schwarz J; Brejcha M; Kozmon P; Pospíšilová S; Brychtová Y; Pospíšil Z; Trněný M
    Eur J Haematol; 2011 Aug; 87(2):130-7. PubMed ID: 21535162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel.
    Reddy KS
    Br J Haematol; 2006 Mar; 132(6):705-22. PubMed ID: 16487171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course.
    Stilgenbauer S; Bullinger L; Lichter P; Döhner H;
    Leukemia; 2002 Jun; 16(6):993-1007. PubMed ID: 12040431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of 5'IGH deletions in B-cell chronic lymphocytic leukemia.
    Quintero-Rivera F; Nooraie F; Rao PN
    Cancer Genet Cytogenet; 2009 Apr; 190(1):33-9. PubMed ID: 19264231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and outcome of Chinese patients with monoclonal B-cell lymphocytosis.
    Xu W; Li JY; Wu YJ; Cao X; Fan L; Qiao C; Liu Q; Yao L; Miao KR
    Leuk Res; 2009 Dec; 33(12):1619-22. PubMed ID: 19250675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.
    Cuneo A; Bigoni R; Rigolin GM; Roberti MG; Bardi A; Cavazzini F; Milani R; Minotto C; Tieghi A; Della Porta M; Agostini P; Tammiso E; Negrini M; Castoldi G
    Haematologica; 2002 Jan; 87(1):44-51. PubMed ID: 11801464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.